PAVmed (NASDAQ: PAVM) — Perfil da empresa, notícias e dados financeiros
PAVmed focuses on innovative medical technology, including diagnostics and minimally invasive devices, to enhance patient care.
PAVmed
PAVmed (NASDAQ:PAVM) is a diversified medical technology company with a focus on developing and commercializing innovative diagnostics and medical devices across various medical areas. PAVmed's portfolio spans from minimally invasive devices, digital health products to next-generation diagnostics, showcasing their commitment to improving patient outcomes while reducing healthcare costs. Among their groundbreaking projects are the EsoGuard Esophageal DNA Test aimed at early detection of esophageal precancer conditions and the CarpX device, designed to treat carpal tunnel syndrome with a minimally invasive approach. PAVmed's objectives are centered on leveraging their multi-disciplinary approach to rapidly advance healthcare innovations from concept to commercialization, enhancing patient care on a global scale.
Resumo
Operações
Produtos e/ou serviços de PAVmed
- CarpX is a device for minimally invasive treatment of Carpal Tunnel Syndrome, providing relief without traditional surgery.
- EsoGuard is a non-invasive test designed to detect esophageal precancerous conditions using a simple esophageal cell collection device.
- EsoCheck is a novel, patient-friendly device intended to collect cells from the esophagus for DNA analysis, aiming to detect Barrett's Esophagus.
- DisappEAR is an antimicrobial, resorbable ear tube made from a proprietary silk-derived protein for treating recurrent ear infections.
- PortIO is an implantable intraosseous vascular access device, providing long-term access without the complications of traditional central venous catheters.
- Lucid Diagnostics focuses on commercializing EsoGuard and EsoCheck tests, aiming to prevent esophageal cancer through early detection.
equipe executiva do PAVmed
- Lishan AklogChairman & CEO
- Dennis M. McGrathPresident & CFO
- Shaun M. O'NeillExecutive VP & COO
- Michael Adam GordonExecutive VP, General Counsel & Secretary
- Brian J. deGuzmanExecutive VP, Chief Technology & Compliance Officer
- Suman M. VermaSenior VP of Molecular Genetics & Chief Scientific Officer
- Matthew RileySenior Director of Investor Relations
- Deepika A. LakhaniSenior VP, Chief Regulatory & Quality Officer
- Victoria T. LeeExecutive Vice President & Chief Medical Officer
- Joseph VirgilioSVP & Chief Business Officer of Medical Devices
Principais indicadores financeiros
Resultados divulgados pela PAVmed, em USD.
- Cap. de mercado
- 17,1 mi
- Receita (TTM)
- 112 mil
- P/L
- —
- LPA (diluído, TTM)
- -14.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 71 mil | -21,8 mi | 401 mil | |
| 3 mi | -44,5 mi | 39,8 mi | |
| 2,5 mi | -68,8 mi | -64,2 mi | |
| 377 mil | -91,1 mi | -89 mi |